Bionxt Solutions Inc. is a Canada-based bioscience company headquartered in Vancouver, specializing in advanced drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. The company engages in research, development, manufacture, and sale of next-generation drug formulations, including sublingual thin films, transdermal patches, oral dissolvable tablets, and targeted chemotherapy systems that deliver active compounds directly to tumor tissue while reducing exposure to healthy cells. Its product pipeline features formulations such as BNT23001 for multiple sclerosis, BNT23002 for myasthenia gravis, BNT24002 for lupus nephritis, BNT24003 for rheumatoid arthritis, and BNT24004 for longevity and anti-aging applications, primarily targeting neurological and autoimmune diseases to enhance patient compliance and bioavailability. Bionxt Solutions Inc. also provides diagnostic screening tests for infectious diseases and oral health, along with standardization and clinical evaluation of emerging active pharmaceutical ingredients. Operating in pharmaceutical sectors across regions including Austria, Germany, Switzerland, and Korea, it plays a role in innovating drug administration for improved therapeutic outcomes.